Dawn Carter Bir - Jan 3, 2022 Form 4 Insider Report for REATA PHARMACEUTICALS INC (RETA)

Role
Chief Commercial Officer
Signature
/s/ Tracy Herson, attorney-in-fact
Stock symbol
RETA
Transactions as of
Jan 3, 2022
Transactions value $
$0
Form type
4
Date filed
1/5/2022, 03:09 PM
Previous filing
May 13, 2021
Next filing
May 11, 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RETA Class A common stock Award $0 +35K $0.00 35K Jan 3, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RETA Employee Stock Option (right to buy) Award $0 +70K $0.00 70K Jan 3, 2022 Class A common stock 70K $27.32 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares represent Restricted Stock Units, which vest in sixteen equal quarterly installments beginning on April 3, 2022, subject to continued service through each vesting date.
F2 The options vest in sixteen equal quarterly installments beginning on April 3, 2022, subject to continued service through each vesting date.